Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | HTR6 | P50406 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604791 | 0.87 | CA1 (0.46) | BRD4HTR6CYP2C19ALDH3A1PKM | |
| SCHEMBL14685251 | 0.87 | CA1 (0.46) | BRD4HTR6CYP2C19ALDH3A1PKM | |
| SCHEMBL1887325 | 0.84 | BRD4 (0.58) | BRD4HTR6CYP2C19DRD2HTR2A | |
| SCHEMBL15607451 | 0.84 | BRD4 (0.43) | BRD4HTR6CYP2C19DRD2HTR2A | |
| SCHEMBL1772583 | 0.80 | AGTR1 (0.43) | BRD4PKMMET | |
| SCHEMBL3348657 | 0.79 | CA1 (0.40) | BRD4HTR6CYP2C19DRD2HTR2A | |
| SCHEMBL1585468 | 0.78 | HTR6 (0.40) | BRD4HTR6CYP2C19DRD2HTR2A | |
| SCHEMBL1049380 | 0.78 | HTR6 (0.55) | HTR6CYP2C19DRD2HTR2AHTR7 | |
| SCHEMBL3506020 | 0.77 | PDPK1 (0.54) | BRD4HTR6MET | |
| SCHEMBL14687940 | 0.77 | MEN1 (0.47) | BRD4HTR6DRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BRD4 517/4885HTR6 3675/4885CYP2C19 2766/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BRD4 517/4885HTR6 3675/4885CYP2C19 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.